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Background: The development of serum immunoassays for the measurement of immunoglobulin free light chains
has led to a paradigm shift in the diagnosis, assessment and monitoring of patients with plasma cell dyscrasias. The
impact of these immunoassays which employ polyclonal antibodies was most notable for those patients who were
previously classified as non-secretory multiple myeloma. Recently new monoclonal antibody based assays have
become available. The purpose of this study was to compare the diagnostic sensitivity of these new assays with
those already in clinical practice.
Methods: Sera from 30 patients who present with severe acute kidney injury and multiple myeloma were
identified for analysis. A head to head comparison of the two commercially available free light chains assays was
then undertaken to determine if their diagnostic sensitivity and specificity were comparable.
Results: In this first assessment of the utility of these new assays, we found that one of 17 patients with a lambda
monoclonal free light chain resulting in acute kidney injury were not identified and a further 12% of patients were
wrongly classified as having levels below those associated with disease specific acute kidney injury.
Conclusion: These results suggest that caution should be applied to the use of new free light chain assays in the
assessment of patients with a monoclonal gammopathy.
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The development of polyclonal nephelometric immu-
noassays for the measurement of free immunoglobulin
light chains (FLC) in the serum has changed screening
algorithms, classifications and the monitoring of a num-
ber of plasma cell dyscrasias [1-3]. These assays, which
utilise latex-conjugated polyclonal antisera, when com-
bined with serum protein electrophoresis provide a sen-
sitive screening tool for plasma cell dyscrasias. Together
they identify all cases of multiple myeloma, 96% of AL-
amyloidosis and 85% of monoclonal gammopathy of un-
determined significance (MGUS) [4]. These FLC assays
have a particular role for the diagnosis and monitoring* Correspondence: c.a.hutchison@bham.ac.uk
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distribution, and reproduction in any mediumof light chain only multiple myeloma [1], but in addition
their sensitivity has lead to the development of a new
classification of response of multiple myeloma: stringent
complete response (when the FLC ratio has normalised,
in addition to standard parameters). Furthermore the as-
sessment of serum FLC provides an additional tool for
the risk stratification of MGUS [5] and asymptomatic
myeloma [6] and has allowed the description of a new
class of FLC only MGUS [7].
Monoclonal serum FLC exhibit different inter-patient
[8] and intra-patient [9] physio-chemical properties.
This may reflect the genetic [10] and biological diver-
sity of the FLC’s and contribute to one of the most sig-
nificant complications of monoclonal FLC, acute kidney
injury (AKI) secondary to cast nephropathy; when se-
vere this has a profound impact on morbidity and mor-
tality and reduces quality of life. The rapid diagnosis of
AKI due to myeloma cast nephropathy facilitated bytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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specific treatment [11]. Recent work has demonstrated
that when treatments are targeted to provide a rapid
reduction in circulating concentrations of monoclonal
FLC renal recovery occurs in the majority of patients
[12-15].
Recently, new immunoassays which use monoclonal
antibodies against FLC have become commercially avail-
able. The purpose of this study was to compare the diag-
nostic sensitivity of these new monoclonal assays with
the established polyclonal FLC assays in the context ofFigure 1 Comparison of established (Freelite) and novel (Siemens) se
and acute kidney injury. The new serum FLC assays did not identify neph
largely this can be explained by the poor performance of the lambda assay
reasonable (C).individuals presenting with new severe AKI secondary to
multiple myeloma where there is a clear need for a rapid
diagnosis.
Results and discussion
The purpose of this study was to compare the diagnostic
sensitivity of the two commercially available immunoas-
says for the identification of monoclonal FLC, in patients
with severe AKI and multiple myeloma. Similar refer-
ence range comparisons between the two assays had
previously been reported [16], therefore for these assaysrum free light chain assays in patients with multiple myeloma
rotoxic levels of monoclonal FLCs in 18% of patients studied (A),
(B). In comparison the correlation of the kappa assays was









κ λ Ratio κ λ Ratio
2 Free λ 2 7010 0.0003 1 322 0.003 No Yes
7 IgA λ 8 1810 0.0044 4 1 8.058 Yes Yes
10 IgG λ 8 1080 0.0078 9 64 0.134 No Yes
13 IgG λ 9 572 0.0162 9 225 0.041 No Yes
23 IgG κ 796 6 125.7 493 17 29.6 No Yes
*Patients were classified as missed FLC if the new assays did not identify a
monoclonal FLC.
**Patients were classified as misclassified if their monoclonal FLC level was
reported as less than the nephrotoxic level of 500 mg/L (5 of 28 patients).
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clinical cut-offs identified by the predicate assays. Sera
from 30 patients with severe AKI and multiple myeloma
were available for analysis. Patients had a median age of
68.5 years and 70% were male. Seventeen patients had a
monoclonal λ FLC, 11 patients had a monoclonal κ FLC
and two patients had no demonstrable monoclonal FLC
(Table). The renal diagnoses in the two patients without
a monoclonal FLC were acute tubular necrosis in the
context of severe infection and obstructive nephropathy,
respectively. In the remaining 28 patients the cause of
the AKI was attributed to multiple myeloma and a
nephrotoxic FLC (Figure 1A).
The established FLC assays, which utilise polyclonal
antibodies, have high rates of diagnostic sensitivity in
patients with myeloma kidney [11], multiple myeloma,
AL-amyloidosis and MGUS [17]. In this first clinical
comparison of the established assays with the new
assays, which use monoclonal antibodies, we found one
of the seventeen patients (6%) with a monoclonal λ FLC
was miss-classified by the assay (Tables 1 and 2). The
patient and 7, had 1810 mg/L of λ FLC with the historic
assays and 1 mg/L λ FLC / 4 mg/L κ FLC by the new
assay incorrectly indicating a kappa clone, in accordance
with manufacturers instructions antigen excess checks
were not performed. All patients with a monoclonal κ
FLC were identified with the new assay. The missed case
of λ FLC monoclonality indicates the limitation of using
monoclonal antibodies, as they have a limited number of
epitopes which they can identify; the myriad structural
variations in monoclonal FLC means that there will be
cases where a monoclonal antibody based assay will not
detect FLC clonality; this case is a practical demonstra-
tion of this principle.
The correlation coefficient of the two FLC assays
was less good for patients with monoclonal λ FLC
(Figure 1B) than for patients with monoclonal κ FLC
(Figure 1C): r = 0.617, p < 0.003 and r = 0.843, p = 0.001
respectively. The correlation of the FLC ratios between
the two assays was 0.894, P < 0.01. The shortfalls inTable 1 Summary for comparison of diagnostic accuracies
between the two free light chain assays in patients with
multiple myeloma and acute kidney injury
Siemens % misclassified by
Siemens TestYes No
LCMM Freelite Yes 7 1 12.5%
No 0 0
IIMM Yes 17 4 19%
No 0 0
The table above shows the number of patients that tested positive or negative
with the Freelite and Siemens FLC assays. The Siemens FLC assay misclassified
5/28 patients with monoclonal FLC >500 mg/L. LCMM – light chain multiple
myeloma, IIMM – intact immunoglobulin multiple myeloma.correlations of the absolute values of FLC are relevant
for both the diagnosis and monitoring of patients.
First, five of the 28 patients (18%) with AKI secondary
to multiple myeloma were misclassified by the new
assays as having FLC levels below the nephrotoxic
threshold of 500 mg/L, four of these patients had a
monoclonal λ FLC and one had a monoclonal κ FLC.
Second, disease response as defined by the reduction
in serum FLC levels is increasing in importance in all
patients with multiple myeloma, but has particularly
relevance in those with AKI where an early reduction
in monoclonal FLC both guides treatment and suggests
outcome [12-15]. It is imperative therefore that the
established ‘risk’ and ‘response’ levels of the original
FLC assays cannot be used for the new FLC assays.
Rather levels specific for the new assays should now
be identified. Clinicians will then need to be made
aware of these new levels and informed which assay
their laboratory is using.
The principal limitation of this work is the small
population size. Further work should now be under-
taken to assess these new monoclonal assays in larger
populations and specific disease groups such as AL-
amyloid, where the potentially inferior performance of
the new λ assay may be of particular importance. In
addition, the correlations between these assays are not
robust enough to apply the current definitions of mye-
loma response based on FLC monoclonality from the
new assays.
Conclusion
This study highlights the importance of large compara-
tive studies of new immunoassays before they are used
in clinical practice. This provisional work demonstrated
that the new monoclonal N-latex assay for FLC meas-
urement did not robustly replicate the results of the
established polyclonal FLC assays. Further work is now
required before these new assays can be adopted into
clinical practice.
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This study was undertaken as a service evaluation at the
University Hospital Birmingham. All data analysis was
coded and anonymised. Sera from patients, who presented
with new dialysis dependent renal failure, to the renal unit
at the University Hospital Birmingham, were screened for
inclusion in a trial assessing the management of severe
renal failure in multiple myeloma (COREC 05/Q2706/107,
South Birmingham Research Ethics Committee), results of
which have been reported previously [14,18,19].
Study populations
Dialysis-dependent renal failure was defined as an esti-
mated GFR of <15mls/min/1.73 m2, as calculated by the
abbreviated MDRD equation and a clinical or metabolic
requirement for dialysis as identified by the reviewing
nephrologist [20]. Attribution of the cause of renal fail-
ure to multiple myeloma was based on renal histology
or in cases where a renal biopsy was contraindicated
when all other potential causes were excluded. The clin-
ical diagnosis of multiple myeloma was made by a con-
sultant haematologist in accordance with international
diagnostic criteria [21].
Laboratory and statistical analysis
Serum samples were stored at −80°C until thawed for the
current study; previous work has demonstrated the stability
of FLC concentrations in urine samples over many years
[22] and apparent stability in serum samples [17]. Serum κ
and λ FLC concentrations were measured by nephelome-
try, on a Dade-Behring BN™II Analyser, using particle-
enhanced, high-specificity, homogeneous immunoassays
(Freelite™, The Binding Site Group Ltd, Birmingham, UK
[23] and N-Latex FLC, Siemens Healthcare Diagnostic
Products GmBh, Germany). FLC results were compared
with the published reference range for the FLC ratio in
patients with renal failure reference range (0.37-3.17) [24].
Data were analysed using SPSS 17.0 for Windows.
Spearman’s correlation coefficient was used to assess the
correlation of results between the two assays and Chi
square test to assess the classification of the patients by
the two assays.
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